McKesson (MCK)
McKesson (MCK)
One-line summary: One of the "Big Three" US drug wholesalers; franchises Health Mart, a network of ~4,000 independent community pharmacies — the channel that state NADAC-floor laws are designed to keep alive.
What it is
McKesson (NYSE: MCK) is a pharmaceutical distributor and healthcare services company, one of the Big Three alongside Cencora (cencora) and Cardinal Health. Beyond distribution it franchises Health Mart — "nearly 4,000 high-performing, locally owned independent community pharmacies" — and operates Health Mart Atlas as its Part D network access vehicle.
Why it matters to stock-market
MCK is the candidate beneficiary at the end of the chain state-nadac-floor-reimbursement-mandates implies: state laws mandating NADAC + $10.05–$15 dispensing fees make it illegal to reimburse pharmacies below acquisition cost, which should decelerate the independent-pharmacy closures (1,200+ since 2013) that have been shrinking MCK's franchise channel.
The margin logic that makes it interesting is a genuine asymmetry: wholesalers earn their thinnest sell-side discounts — i.e. their best margin — on small pharmacies (~98% of WAC to independents vs ~94% to large chains), and receive the "lowest buy-side distribution fees (as a share of cost) for brand-name products sold by the largest manufacturers," which compresses margin when serving major chains. So an independent-pharmacy channel that stops shrinking is worth disproportionately more to MCK than raw script count implies.
⚠ That last inference is exactly what is not established — see below. This entity is on the map as a lead, not a thesis.
Key facts
All from 2026-07-17-autoresearch-pbm-pass-through-preemption-profit-pool-migration.
- Health Mart: "nearly 4,000 high-performing, locally owned independent community pharmacies" (McKesson).
- The margin asymmetry (Drug Channels): wholesalers price brand drugs to large chains at ~94% of WAC (6% sell-side discount) but cut GLP-1 discounts for smaller pharmacies to only 98% of WAC (2%); PBM reimbursements to pharmacies "typically average 96% of WAC or lower" — so independents often dispense below acquisition cost. Wholesalers also earn the "lowest buy-side distribution fees (as a share of cost) for brand-name products sold by the largest manufacturers."
- Customer concentration: CVS ≈ 31% of McKesson's US distribution (Drug Channels) — i.e. MCK's largest customer is also the PBM-insurer on the risk side of the same chain.
- Part D network position is deteriorating: Health Mart Atlas "participates directly in only two HCSC plans with members otherwise non-preferred" (Drug Channels, 2026-02).
Weaknesses (from a thesis-input perspective)
- ⚠ The beneficiary link is an unverified inferential leap. The autoresearch is explicit: "No source in this pass quantifies wholesaler earnings sensitivity to independent-pharmacy count, and no MCK/COR/CAH management commentary from the past 30 days surfaced connecting state NADAC floors to their outlook... Do not emit a signal on Chain B without sizing this."
- Counter-evidence cuts against it, from MCK's own strategy. The Big Three have spent over $16 billion since 2013 acquiring or partnering with physician-practice MSOs precisely because traditional distribution is thin-margin ("buy low, sell high, collect early, pay late") and clinical services are "higher-margin... reducing dependency on distribution spreads." MCK's stated growth strategy points away from the retail distribution channel this thesis would have it lever into.
- Independents are walking away from Part D networks at the same moment state law improves their commercial economics — the two trends partly offset.
- CVS at ~31% of US distribution means MCK has material exposure to the risk side of the PBM chain, not just the beneficiary side.
Open questions
- What is MCK's earnings sensitivity to independent-pharmacy count? Unquantified anywhere — the gating question.
- Does management connect state NADAC floors to outlook on any recent call?
- Does the Health Mart channel's Part D exclusion offset the commercial-market improvement?